Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.a.

Lisapharma Spa

Giorgio G Zagnoli

Paolo Colombo

Ubaldo Conte

Fabrizio Cudazzo

Carla Caramella

Loretta Maggi

Sucralfate gel in the dry state in porous granular form having a particle-size distribution of between 100 and 1000 &mgr;m, an apparent density of the powder bed of between 0.7 and 0.9 g/ml, a settling index of between 5 and 15%, and a residual humidity of between 5 and 15%, and the corresponding process of preparation, which comprises a treatment with microwaves of a diluted solution of powdered sucralfate gel, with a sucralfate titer of between 20 and 70 wt. %. This solid product may be advantageously used in the preparation of solid pharmaceutical compositions that contain it as single active principle, or else as coating of solid compositions that contain, as active principle, a substance that may cause lesions to the gastric mucosa.

Process for the preparation of granular and porous sucralfate dry gel

Sucralfate gel in the dry state in porous granular form having a particle-size distribution of between 100 and 1000 &mgr;m, an apparent density of the powder bed of between 0.7 and 0.9 g/ml, a settling index of between 5 and 15%, and a residual humidity of between 5 and 15%, and the corresponding process of preparation, which comprises a treatment with microwaves of a diluted solution of powdered sucralfate gel, with a sucralfate titre of between 20 and 70 wt. %. This solid product may be advantageously used in the preparation of solid pharmaceutical compositions that contain it as single active principle, or else as coating of solid compositions that contain, as active principle, a substance that may cause lesions to the gastric mucosa.

Antacid pharmaceutical composition in the form of a suspension based on

Pharmaceutical compositions in the form of stable sucralfate suspensions free of suspending agents, wherein the sucralfate is present in the form of a gel having self-suspending properties and is suspended in an aqueous carbohydrate solution in a quantity of between 1 and 40% of sucralfate by weight. Said gel has a surface area exceeding 200 m.sup.2 /g and is prepared by dissolving powdered sucralfate in an HCl solution and then precipitating it with an NaOH solution added to a pH of between 4 and 4.5.

Pharmaceutical compositions in the form of stable sucralfate suspensions

The use of sucralfate humid gel is described as vehicle for the application f drugs having topic activity (dermic and mucosal) and as basis for the formulation of beauty masks and other cosmetic preparations. Therapeutic and cosmetic formulations are described in the form of creams, ointments, aqueous dispersions comprising sucralfate humid gel.

Use of sucralfate humid gel as vehicle for drugs having topic activity

This invention relates to the vaginal topical use of lysine p-isobutylphepropionate in local and targeted anti-inflammatory treatment of pathologies of obstetric and gynelogical type. Said use is effective in the treatment of patients with inflammatory forms having either aspecific or specific etiology, and also in the treatment both of patients of medical pertinence and of patients of surgical pertinence. The lysine p-isobutylphenylpropionate is used in the form of an aqueous solution for vaginal washes or in other pharmaceutical forms for vaginal use such as globules, suppositories etc.

Topical vaginal use of lysine p-isobutylphenylpropionate in

The present invention relates to a novel pharmacologically active salt derivative, constituted by 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxy-phenyl)-1-butanone 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde-5-phosphate, to the process for the production thereof, and to the related pharmaceutical compositions. Said salt derivative is produced by reacting 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde-5-phosphoric acid with 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-3-butanone in an organic solvent and subsequently crystallizing the reaction product. Said salt derivative carries out an important pharmacological activity as inhibitor of platelet aggregation with vasodilative action.

Growing community of inventors

Como, Italy

Giorgio G Zagnoli